This article was originally published in The Gray Sheet
Executive SummaryTemperature-based targeted cryosurgery product used in four-year study shows an 85% success rate in treating confined prostate cancer in 586 patients. Over 500 subjects remained "cancer-free" following the temperature monitored "freezing" of cancerous tissue, Fred Lee, MD, Crittendon Hospital, Rochester, New York, says in a Aug. 4 Endocare release. He notes that prostate specific antigen rates for patients receiving the minimally invasive treatment were "virtually undetectable" (0.18 ng/ml) and that 98% of treated patients required only an overnight stay following treatment
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.